이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Celltrion gains production foothold in U.S. with Baxter CMO deal

Collected: 2017.11.03

Distributed: 2017.11.06

Source: Go Direct

South Korea’s Celltrion Inc. Friday said it has signed a contract with BioPharma Solutions (BPS), a contract manufacturing organization of U.S. pharmaceutical company Baxter to produce its biosimilar Remsima directly in the U.S.

The deal is expected to save distribution costs and stabilize the supply of the rheumatoid arthritis drug to the world’s largest pharmaceutical market, according to Celltrion.

At 2:05 p.m. Friday, shares of Celltrion were up 1.2 percent at 174,500 won ($156.7)

Under the agreement, BPS will be responsible for sterile fill of vials, packaging, and other contract manufacturing to roll out Remsima in the U.S.

The two companies also agreed to discuss expanding their CMO partnership to include Celltrion’s other biosimilars such as Truxima and Herzuma after regulatory approval of them by U.S. health authorities. Supply priority will be given to products from BPS for the U.S. market over Celltrion’s shipment from its home market.

“With the contract, we have gained a production foothold for America, the world’s largest pharmaceutical market, allowing us to better respond to local market dynamics,” said a Celltrion official.

Remsima, a biosimilar of Remicade (infliximab) developed by Johnson & Johnson`s subsidiary, Janssen Biotech, is indicated for the treatment of patients with rheumatoid arthritis, Crohn’s disease and other autoimmune diseases. Remsima was launched in the U.S. late last year after the FDA’s approval in the same year.

By Kim Hye-soon and Minu Kim

List

Previous: DGB Financial Group to take over HI Investment & Securities for $400 mn

Next: CJ Group offering to sell CJ HealthCare